The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation Appendix Tables (S1 to S2 P=0.0005, anti-CD3 0.005 µg/ml: 0.5 µg/ml anti-NKG2D versus 0.0 µg/ml anti-NKG2D P=0.0309; right panel: anti-CD3 0.005 µg/ml: 0.5 µg/ml anti-NKG2D versus 0.0 µg/ml anti-NKG2D P=0.0205) (C) A mIgG1 isotype control was also used in parallel. Thus, NKG2D-mediated co-stimulation was effective when the anti-CD3 mAb was limited (0.01 and 0.005 µg/ml). The anti-NKG2D mAb induced more proliferation and IL-2 release when used in lower concentration (0.5 µg/ml compared to 1.0 µg/ml).
Notably, anti-NKG2D co-stimulation induced a proliferation even at 0.1 µg/ml were the anti-CD28 mAb was not able anymore to elicit a significant proliferation. Appendix Figure S14 . Impairment of NKG2D-mediated co-stimulation of CD8 + T cells by NKG2D-counter-regulation. Purified CD8 + T cells were cultured on plate-bound anti-NKG2D (1 µg/ml) or an isotype control (IgG1) for 24 h before the NKG2D expression was measured by flow cytometry. These 9 CD8 + T cells were subsequently stained with CFSE and cultured on plates coated with anti-CD3 mAb (0.005 or 0.01 µg/ml) in combination with anti-CD28 (0.5 µg/ml) mAb as positive control or anti-NKG2D mAb (0.5 µg/ml). Proliferation was measured after 72 h by flow cytometry. The means and SD (n=6) of cell divisions is shown as evaluated in parallel to the MFI (see Fig 7D) . Differences between CD8 + T cells pre-exposed to anti-NKG2D and isotype control (mIgG1) were obvious in these experiments (red boxes).
Appendix Figure S13. Correlation of NKG2D expression on CD8 + T cells with L-MICA-129Val and L-

MICA-129Met expression on target cells. (A) NKG2D expression on purified CD8
Appendix Figure S15 . Characterization of purified IL-2-stimulated NK cells and purified CD8 + T cells. anti-CD3 1.0 µg/ml anti-CD3 0.5 µg/ml anti-CD3 0.1 µg/ml anti-CD3 0.05 µg/ml anti-CD3 0.01 µg/ml anti-CD3 0.005 µg/ml anti-CD28 1.0 µg/ml anti-CD28 0.5 µg/ml anti-CD28 0.1 µg/ml anti-NKG2D 1.0 µg/ml anti-NKG2D 0.5 µg/ml anti-NKG2D 0.1 µg/ml mIgG1 1.0 µg/ml mIgG1 0.5 µg/ml mIgG1 0.1 µg/ml MICA-129Met-Fc 1.0 µg/ml MICA-129Met-Fc 0.5 µg/ml MICA-129Met-Fc 0.1 µg/ml MICA-129Val-Fc 1.0 µg/ml MICA-129Val-Fc 0.5 µg/ml MICA-129Val-Fc 0.1 µg/ml OVA-Fc 1.0 µg/ml OVA-Fc 0.5 µg/ml OVA-Fc 0.1 µg/ml mIgG2a 1.0 µg/ml mIgG2a 0.5 µg/ml mIgG2a 0.1 µg/ml CFSE [% MFI of control] anti-CD3 0.5 µg/ml anti-CD3 0.1 µg/ml anti-CD3 0.05 µg/ml anti-CD3 0.01 µg/ml anti-CD3 0.005 µg/ml anti-CD28 1.0 µg/ml anti-CD28 0.5 µg/ml anti-CD28 0.1 µg/ml anti-NKG2D 1.0 µg/ml anti-NKG2D 0.5 µg/ml anti-NKG2D 0.1 µg/ml mIgG1 1.0 µg/ml mIgG1 0.5 µg/ml mIgG1 0.1 µg/ml MICA-129Met-Fc 1.0 µg/ml MICA-129Met-Fc 0.5 µg/ml MICA-129Met-Fc 0.1 µg/ml MICA-129Val-Fc 1.0 µg/ml MICA-129Val-Fc 0.5 µg/ml MICA-129Val-Fc 0.1 µg/ml OVA-Fc 1.0 µg/ml OVA-Fc 0.5 µg/ml OVA-Fc 0.1 µg/ml mIgG2a 1.0 µg/ml mIgG2a 0.5 µg/ml mIgG2a 0.1 µg/ml 
